Wells Fargo analyst Michael Sison raised the firm’s price target on Celanese to $195 from $180 and keeps an Overweight rating on the shares. Acetyl dynamics appear to have bottomed and the firm still sees a ramp in EPS during the second quarter vs. the first quarter, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CE:
- Celanese, Secarna Pharmaceuticals enter RNA research collaboration
- Celanese, Secarna in RNA research collaboratioon for ASO therapies
- William M. Brown Exits Celanese Board for 3M CEO Role
- Celanese Corp Welcomes Timothy Go to Expanded Board
- Moderna downgraded, Gap upgraded: Wall Street’s top analyst calls
